These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 4833918)

  • 21. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of MOPC 104E myeloma in plateau phase.
    Ghanta VK; Hiramoto RN; Davis DW; Hiramoto NS
    Cancer Res; 1980 Jul; 40(7):2372-6. PubMed ID: 7190063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of immune response to sheep red blood cells on plasmacytoma MOPC 104 E.
    Ghanta VK; Hiramoto NS; Hiramoto RN
    Cancer Res; 1981 Jun; 41(6):2197-9. PubMed ID: 7237419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth characteristics of a mouse plasma cell tumor.
    Bergsagel DE; Valeriote FA
    Cancer Res; 1968 Nov; 28(11):2187-96. PubMed ID: 5723963
    [No Abstract]   [Full Text] [Related]  

  • 25. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunomodulation of antitumor response by chemotherapy.
    Ben-Efraim S
    Contrib Gynecol Obstet; 1985; 14():199-205. PubMed ID: 2933224
    [No Abstract]   [Full Text] [Related]  

  • 28. Regulation of immune responses aginst the syngeneic ADJ-PC-5 plasmacytoma in BALB-c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis.
    Haubeck HD; Kölsch E
    Immunology; 1982 Nov; 47(3):503-10. PubMed ID: 6215340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surface immunoglobulins on circulating lymphocytes in mouse and human plasmacytoma.
    Heller P; Yakulis V; Bhoopalam N; Costea N; Cabana V; Nathan RD
    Trans Assoc Am Physicians; 1972; 85():192-202. PubMed ID: 4633774
    [No Abstract]   [Full Text] [Related]  

  • 30. Kinetics of cancer cell kill by chemotherapeutic agents in vivo.
    Wilcox WS
    Natl Cancer Inst Monogr; 1967 Feb; 24():257-69. PubMed ID: 6021080
    [No Abstract]   [Full Text] [Related]  

  • 31. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression.
    Gorczynski RM; Kennedy M; Ciampi A
    J Immunol; 1985 Jun; 134(6):4261-6. PubMed ID: 2859337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents.
    Valeriote F; Lynch R; Berger NA; White E; Coulter D
    J Natl Cancer Inst; 1981 Jun; 66(6):1083-8. PubMed ID: 7017213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors.
    Schabel FM
    Cancer Res; 1969 Dec; 29(12):2384-9. PubMed ID: 5369685
    [No Abstract]   [Full Text] [Related]  

  • 34. Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer.
    Frondoza CG; Trivedi SM; Humphrey RL
    Cancer Res; 1979 Jul; 39(7 Pt 1):2497-500. PubMed ID: 445451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a zinc-deficient diet on the growth of an IgM-secreting plasmacytoma (TEPC-183).
    Fenton MR; Burke JP; Tursi FD; Arena FP
    J Natl Cancer Inst; 1980 Dec; 65(6):1271-2. PubMed ID: 6933272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
    Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
    Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A quantitative model for the study of the growth and treatment of a tumor and its metastases with correlation between proliferative state and sensitivity to cyclophosphamide.
    DeWys WD
    Cancer Res; 1972 Feb; 32(2):367-73. PubMed ID: 5058192
    [No Abstract]   [Full Text] [Related]  

  • 39. Delayed hematological recovery after cyclophosphamide treatment in the presence of an advanced tumor.
    DeWys WD; Mansky JM
    Cancer Res; 1973 Nov; 33(11):2662-7. PubMed ID: 4748427
    [No Abstract]   [Full Text] [Related]  

  • 40. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.